Androgen-ablation is standard therapy for metastatic prostate cancer because 80% patients show an initial response to such a treatment. However, this therapy is rarely curative because metastatic cancer within an individual patient is heterogeneous, including both androgen-dependent and -independent prostatic cancer cells even before therapy is initiated. Elevation of intracellular Ca2+ levels following androgen-ablation seems necessary for apoptosis in prostatic cells. Androgen-ablation does not induce elevated intracellular Ca2+ levels in the androgen-independent cells presumably due to a block in the proximal events. However, elevation of intracellular Ca2+ by ionomycin can cause apoptosis in the androgen-independent Dunning R-3327 AT-3 rat prostatic cancer cells, suggesting that events downstream of Ca2+ elevation may be common to the apoptotic process in androgen-dependent cells subjected to androgen- ablation and androgen-independent cells exposed to ionomycin. By differential hybridization and Northern analysis, we have identified a common set of genes induced in both androgen-dependent and -independent cells. One of these genes, designated prostate apoptosis-response-4 (par- 4) was found to be induced only by effectors of apoptosis and not by growth-stimulatory, growth arrest, or oxidative stress signals. We hypothesize that par-4 is an apoptosis-response-specific gene, and is likely to be functionally involved in apoptosis. The function of par-4 in ionomycin-driven apoptosis in AT-3 cells will be determined by performing transfection studies with appropriate constructs for antisense inhibition or overexpression of this gene. We will ascertain that in prostate cells parA induction is apoptosis-response-specific, by determining whether this gene is inducible by androgen in rat ventral prostate. Moreover, we will study par-4 expression in diverse in vitro experimental model systems for apoptosis, growth stimulation, growth arrest, differentiation, and stress, to determine whether par-4 induction is apoptosis-specific. We have already shown that par-4 is a novel gene as judged by GenBank search, and that induction of this gene after androgen-ablation in rat ventral prostate is downstream of intracellular Ca2+ levels. This study will be the first step in the direction of delineating Ca2+-driven apoptotic pathways. A cell death-specific gene will be useful clinically as a marker for involution of the prostate and as a candidate for gene therapy of androgen-dependent and androgen- independent prostatic-tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA060872-01A3
Application #
2101652
Study Section
Reproductive Endocrinology Study Section (REN)
Project Start
1995-09-30
Project End
1998-07-31
Budget Start
1995-09-30
Budget End
1996-07-31
Support Year
1
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Kentucky
Department
Surgery
Type
Schools of Medicine
DUNS #
832127323
City
Lexington
State
KY
Country
United States
Zip Code
40506
Pang, Allan H; Obiero, Josiah M; Kulczyk, Arkadiusz W et al. (2018) A crystal structure of coil 1B of vimentin in the filamentous form provides a model of a high-order assembly of a vimentin filament. FEBS J 285:2888-2899
Sviripa, Vitaliy M; Burikhanov, Ravshan; Obiero, Josiah M et al. (2016) Par-4 secretion: stoichiometry of 3-arylquinoline binding to vimentin. Org Biomol Chem 14:74-84
de Thonel, A; Hazoumé, A; Kochin, V et al. (2014) Regulation of the proapoptotic functions of prostate apoptosis response-4 (Par-4) by casein kinase 2 in prostate cancer cells. Cell Death Dis 5:e1016
Burikhanov, Ravshan; Sviripa, Vitaliy M; Hebbar, Nikhil et al. (2014) Arylquins target vimentin to trigger Par-4 secretion for tumor cell apoptosis. Nat Chem Biol 10:924-926
Liu, Yinxing; Gilbert, Misty R; Kyprianou, Natasha et al. (2014) The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells. Acta Neuropathol 128:723-32
Hebbar, Nikhil; Shrestha-Bhattarai, Tripti; Rangnekar, Vivek M (2014) Cancer-selective apoptosis by tumor suppressor par-4. Adv Exp Med Biol 818:155-66
Burikhanov, Ravshan; Shrestha-Bhattarai, Tripti; Hebbar, Nikhil et al. (2014) Paracrine apoptotic effect of p53 mediated by tumor suppressor Par-4. Cell Rep 6:271-7
Hebbar, Nikhil; Shrestha-Bhattarai, Tripti; Rangnekar, Vivek M (2013) Par-4 prevents breast cancer recurrence. Breast Cancer Res 15:314
Shrestha-Bhattarai, Tripti; Hebbar, Nikhil; Rangnekar, Vivek M (2013) Par(-4)oxysm in breast cancer. Cancer Cell 24:3-5
Burikhanov, Ravshan; Shrestha-Bhattarai, Tripti; Qiu, Shirley et al. (2013) Novel mechanism of apoptosis resistance in cancer mediated by extracellular PAR-4. Cancer Res 73:1011-9

Showing the most recent 10 out of 41 publications